Recombinant Human Follicle-Stimulating Hormone in Controlled Ovarian Hyperstimulation with Assisted Reproductive Technology in China: A Cost-Effectiveness Analysis
Hongchao Li,Wei He,Hongbo Lin,Angying Du,Xue Zhang,Han Yang,Shuli Qu
DOI: https://doi.org/10.2147/rmhp.s456277
2024-05-28
Risk Management and Healthcare Policy
Abstract:Hongchao Li, 1 Wei He, 2 Hongbo Lin, 3 Angying Du, 4 Xue Zhang, 5 Han Yang, 5 Shuli Qu 5 1 School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, 211198, People's Republic of China; 2 Fertility and Reproductive Medicine Centre, The Southwest Hospital of AMU, Chongqing, 400038, People's Republic of China; 3 Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036, People's Republic of China; 4 Merck Serono, an Affiliate of Merck KGaA Darmstadt Germany, Beijing, 100016, People's Republic of China; 5 Real-World Solutions, IQVIA, Shanghai, 200041, People's Republic of China Correspondence: Shuli Qu, Real-World Solutions, IQVIA, 1359 Yaolong Road, Shanghai, People's Republic of China, Email Background: To compare the cost-effectiveness of originator (reference) recombinant human follicle stimulating hormone alfa (rhFSH-α) (follitropin alfa, GONAL-f) and its biosimilar (rhFSH, JinSaiHeng) in assisted reproductive technology (ART) from a Chinese patient perspective. Methods: A decision tree model was developed to simulate the treatment pathway of infertile women undergoing ART using GONAL-f or JinSaiHeng. Published clinical and cost data were used to evaluate the cost-effectiveness of the rhFSH-α. The cumulative live birth rate (CLBR), direct medical costs and costs per cumulative live birth were estimated via an analytic decision-tree model. Results: CLBR of GONAL-f was higher than JinSaiHeng preparation (88.3% vs 84.4%), while the cost per cumulative live birth was lower (51,475 vs 52,095 CNY). Conclusion: The originator rhFSH-α was associated with higher CLBR and lower cost per cumulative live birth, with incremental cost per additional live birth of 38,096 CNY (Chinese Yuan). Keywords: recombinant human follicle stimulating hormone, controlled ovarian stimulation, assisted reproductive technology, cost-effectiveness analysis In China, the notable elevation of women's reproductive autonomy, coupled with factors such as marital dynamics and career considerations has precipitated a delay in childbirth. Consequently, there has been a surge in women seeking fertility preservation options and assisted reproductive technology (ART). 1 However, infertility is a heavy burden on individuals and families. In China, the infertility rate has increased from 6.7% in 1988 to 15% in the early 2010s. 2,3 In 2018, the number of infertile women was estimated to exceed 40 million. 3 ART is a commonly used treatment option for women encountering fertility issues. In ART, gonadotropins are critical to follicle development and have a crucial role in optimizing clinical outcomes, such as being directly associated with pregnancy and live birth rate. 4 With a high financial burden, 4 patients and healthcare providers need to understand the cost-effectiveness of gonadotropins to maximize the live birth rate within limited resources. The cumulative live birth rate (CLBR) is proposed to assess IVF program effectiveness, incorporating fresh and thawed frozen embryo transfers. 5 In contrast to the usual "per cycle" or "per embryo transfer" pregnancy reporting, CLBR encompasses total live births. When initial fresh cycles fail, couples inquire about the chance of live birth with further ART. Patients prioritize CLBR as it comprehensively reflects live birth probability throughout treatment, influencing decisions on continuing IVF. 6 In the past decades, commercially available gonadotropin products were generated from human chorionic gonadotropin (hCG) extract, followed by human menopausal gonadotropins (hMG), urinary follicle-stimulating hormone (u-FSH), highly purified hMG, highly purified u-FSH, and recombinant FSH. 4,7 GONAL-f (follitropin α) was the first recombinant human FSH (r-hFSH) authorized in China in 2006. It has the advantages of constant supply, free from urinary protein contaminants, with higher biopotency and overall purity, guaranteed batch-to-batch consistency, high safety, and tolerability. 8–10 JinSaiHeng (recombinant human follitropin for injection) is another gonadotropin that is widely used in China. It is a biosimilar of GONAL-f, entered the market in 2014. By definition, a biosimilar medicine should be biologically similar to its originator. A multi-center, double-blind, randomized clinical trial based on a Chinese population shows that JinSaiHeng is comparable to GONAL-f in terms of the total number of oocytes and follicle growth obtained in a controlled ovarian hyperstimulation (COH) cycle with no statistical difference. 11 For patients and clin -Abstract Truncated-
health care sciences & services,health policy & services